Flag of the European Union EU Clinical Trials Register Help

Clinical trials for abbvie

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    554 result(s) found for: abbvie. Displaying page 6 of 28.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2015-004121-13 Sponsor Protocol Number: M13-687 Start Date*: 2015-11-17
    Sponsor Name:AbbVie GK
    Full Title: A Multicenter Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Investigate Efficacy, Safety and Pharmacokinetics after Dose Escalation in Japanese Subjects with Crohn's Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004876-23 Sponsor Protocol Number: M16-133 Start Date*: 2017-09-13
    Sponsor Name:AbbVie Deutschland
    Full Title: A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir(GLE)/Pibrentasvir(PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1 – 6 ...
    Medical condition: Chronic Hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000074171 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003754-84 Sponsor Protocol Number: M13-774 Start Date*: 2013-04-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe...
    Medical condition: Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001593-15 Sponsor Protocol Number: B15-884 Start Date*: 2016-08-08
    Sponsor Name:Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau
    Full Title: A Multi-center, Randomized, Double blind, Prospective Study to Evaluate the Efficacy and Safety of high induction doses of adalimumab in moderate to severe psoriasis patients. The DEEP study.
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001541-26 Sponsor Protocol Number: M16-106 Start Date*: 2021-05-04
    Sponsor Name:AbbVie Inc
    Full Title: A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
    Medical condition: Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002353-35 Sponsor Protocol Number: M15-462 Start Date*: 2015-11-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Single-Arm, Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally-Impaired Adults with Chronic Hepatitis C Virus Genotype 1 – 6 Infection (EXPEDITION-4)
    Medical condition: Chronic HCV Genotype 1-6 Infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002777-29 Sponsor Protocol Number: M17-377 Start Date*: 2022-10-14
    Sponsor Name:AbbVie Inc
    Full Title: A Phase 3 Randomized, Multicenter, Double-Blind Study to Evaluate the Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects in Japan with Moderate to S...
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001114-26 Sponsor Protocol Number: M14-500 Start Date*: 2014-11-10
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) GB (Completed) SE (Completed) ES (Completed) HU (Completed) IT (Completed) NL (Completed) AT (Completed) GR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002110-12 Sponsor Protocol Number: GO28667 Start Date*: 2014-02-26
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH...
    Medical condition: Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10068852 B-cell chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed) FR (Completed) NL (Completed) HU (Completed) DK (Completed) DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-001690-72 Sponsor Protocol Number: M20-186 Start Date*: 2020-12-21
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Wh...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) DE (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000715-25 Sponsor Protocol Number: M15-340 Start Date*: 2019-04-16
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Polyarticular Course Juvenile Idiopathic Arthritis
    Medical condition: Polyarticular Course Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Restarted) IT (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003942-33 Sponsor Protocol Number: M13-796 Start Date*: 2013-05-03
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk...
    Medical condition: Acute Kidney Injury
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10069339 Acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003797-32 Sponsor Protocol Number: M14-172 Start Date*: 2016-01-25
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITI...
    Medical condition: Chronic Hepatitis C Infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001658-16 Sponsor Protocol Number: M15-534 Start Date*: 2017-04-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 1 Dose Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination with Platinum Doublet Chemotherapy in Subjects with Metastatic or Advanced Non-Small Cel...
    Medical condition: Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001022-14 Sponsor Protocol Number: M14-423 Start Date*: 2014-09-19
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa...
    Medical condition: Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) GB (GB - no longer in EU/EEA) IE (Completed) AT (Completed) ES (Completed) IT (Completed) DE (Completed) NO (Completed) SE (Completed) BE (Completed) FI (Completed) NL (Completed) BG (Completed) PL (Completed) DK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005805-25 Sponsor Protocol Number: M19-771 Start Date*: 2021-11-10
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Subjects with Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation.
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000933-37 Sponsor Protocol Number: M15-925 Start Date*: 2016-11-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Into...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) LV (Completed) PT (Completed) SE (Completed) ES (Ongoing) CZ (Completed) BE (Completed) NL (Completed) SK (Prematurely Ended) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003978-13 Sponsor Protocol Number: M16-852 Start Date*: 2019-09-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis: Select-GCA
    Medical condition: Giant Cell Arteritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10047065 - Vascular disorders 10018250 Giant cell arteritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) AT (Completed) DE (Trial now transitioned) PT (Trial now transitioned) GR (Completed) HU (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003113-94 Sponsor Protocol Number: M16-244 Start Date*: 2016-12-01
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Phase 2 Single-Arm Open-Label Extension Study to Investigate Safety with Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study 1311.5
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FI (Completed) ES (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-006975-41 Sponsor Protocol Number: URONCOR06-24 Start Date*: 2022-07-27
    Sponsor Name:GICOR
    Full Title: Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomise...
    Medical condition: Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:50:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA